Acute hematogenous osteomyelitis in children: recognition and management

Area of Science:

• Pediatrics
• Infectious Diseases
• Musculoskeletal Disorders

Background:

• Acute hematogenous osteomyelitis is common in children, potentially causing lifelong musculoskeletal deformities.
• Staphylococcus aureus is the most frequent causative agent; Haemophilus influenzae type b (Hib) is now rare due to vaccination.
• While MRI is preferred for localized disease, scintigraphy is often the initial choice for locating infection and identifying multifocal disease.

Purpose of the Study:

• To outline current diagnostic and management strategies for acute hematogenous osteomyelitis in children.
• To provide evidence-based recommendations for treatment duration and modality.
• To emphasize the importance of monitoring for complications.

Main Methods:

• Review of diagnostic imaging modalities, including scintigraphy and MRI.
• Discussion of microbiological causes and antibiotic sensitivities.
• Analysis of treatment protocols, including intravenous and oral antibiotic durations and drug choices.
• Consideration of criteria for avoiding bone biopsy/aspiration.

Main Results:

• In typical cases without underlying disease and with a good response to antibiotics, bone aspiration/biopsy may not be necessary.
• First-line antibiotics include beta-lactamase-resistant penicillin; clindamycin or vancomycin are options if community-acquired methicillin-resistant S. aureus (CA-MRSA) is suspected.
• A shortened treatment course of 3 days intravenous followed by 3 weeks of high-dose oral antibiotics is recommended for uncomplicated cases.

Conclusions:

• Effective management of acute hematogenous osteomyelitis can involve a significantly shorter treatment duration than traditionally recommended.
• Careful patient selection and monitoring are crucial for successful outcomes with abbreviated treatment.
• Long-term follow-up (at least 2 years) is essential to detect and manage potential complications.